Loading Events

« All Events

  • This event has passed.

PBSS Minisymposium: Drug-Induced Liver Injury (DILI): Risk Assessment of Drug Candidates and Metabolites in Drug Discovery and Clinical Development

June 2, 2017

Event Navigation

Minisymposium Topics & Speakers:

  • Filling in the Guidance Gaps and Defining Best Practices in monitoring for and diagnosing DILI in clinical trials: The IQ-DILI Consortium – William Treem, MD, J&J
  • The challenges of potential DILI in early clinical development – Michael Rothenberg, MD, PhD, Genentech
  • Liver Toxicity Knowledge Base – A knowledge base approach for drug-induced liver injury – Weida Tong, PhD, NCTR/FDA
  • The role of bile acids in DILI and liver diseases – Yazen Alnouti, PhD, University of Nebraska Medical Center (UNMC)
  • Multi-parametric assessment of hepatotoxicity risk in drug discovery – Donna Dambach, VMD, PhD, Genentech
  • Reactive metabolites: from assessment to removal in drug discovery – Cyrus Khojasteh, PhD, Genentech
  • Risk Assessment for Cholestatic Hepatotoxicity: Integrating Transporter Inhibition and FXR Mediated Regulation into a Predictive In Vitro Assay – Kenneth R. Brouwer, PhD, RPh, Qualyst Transporter Solutions
  • Human Liver Engineering: From Safer Drugs to Liver Regeneration – Gary Peltz, MD, PhD, Stanford University Medical School


June 2, 2017


Pharmaceutical & BioScience Society


Crowne Plaza – Foster City Hotel
1221 Chess Dr.
Foster City, CA 94404 United States